☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Ono Pharmaceutical
Ono Enters into an Option Agreement with Reborna Biosciences for RNA-Targeting Small Molecule to treat CNS Disorders
April 1, 2025
Ono Pharmaceutical Reports the US FDA Approval of Romvimza to Treat Symptomatic Tenosynovial Giant Cell Tumor (TGCT) in Adults
February 17, 2025
Ono Pharmaceutical Reports the EMA’s Acceptance of MAA for Vimseltinib to Treat Tenosynovial Giant Cell Tumor (TGCT)
July 19, 2024
ONO Pharmaceutical Reports Acquisition of Deciphera Pharmaceuticals for $2.4B
April 30, 2024
Ono Pharmaceutical and InveniAI Collaborate to Identify Novel Therapeutic Targets Using Artificial Intelligence (AI) and Machine L...
February 20, 2024
Ono Pharmaceutical and Shattuck Labs Collaborate to Develop Bifunctional Fusion Proteins for Treating Autoimmune and Inflammatory...
February 15, 2024
Ono Pharmaceutical Reports the EMA’s Acceptance of MAA for Vimseltinib to Treat Tenosynovial Giant Cell Tumor (TGCT)
July 19, 2024
PharmaShots' Key Highlights of Second Quarter 2024
July 2, 2024
PharmaShots Weekly Snapshots (April 29 – May 03, 2024)
May 3, 2024
ONO Pharmaceutical Reports Acquisition of Deciphera Pharmaceuticals for $2.4B
April 30, 2024
PharmaShots Weekly Snapshots (February 19 – February 23, 2024)
February 23, 2024
Ono Pharmaceutical and InveniAI Collaborate to Identify Novel Therapeutic Targets Using Artificial Intelligence (AI) and Machine L...
February 20, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.